Current Oncology, Free Full-Text

Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.

Cancer - Wiley Online Library

Current Oncology, Free Full-Text, bronstein méier resultado

Current Oncology An Open Access Journal from MDPI

PDF) Clinical Practice Guidelines in Breast Cancer

Hematology/Oncology articles: The New England Journal of Medicine

Home page Journal of Experimental & Clinical Cancer Research

First-line Atezolizumab Monotherapy Versus Single-agent, 43% OFF

European Journal of Gynaecological Oncology (EJGO)

PDF) Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology

Current Oncology (@CurrentOncology) / X